Table 1.
Patient baseline characteristics (N = 121)
| Group A (n = 59) n (%) | Group B (n = 62) n (%) | Total (n = 121) n (%) | |
|---|---|---|---|
| Sex | |||
| Male | 23 (39) | 15 (24) | 38 (31) |
| Female | 36 (61) | 47 (76) | 83 (69) |
| Age (years) | |||
| Median (range) | 60 (30–86) | 60 (33–80) | 60 (30–86) |
| <65 | 43 (73) | 37 (60) | 80 |
| ≥65 | 16 (27) | 25 (4) | 41 |
| Smoking status | |||
| Never | 45 (76) | 48 (78) | 93 (77) |
| Prior | 10 (17) | 12 (19) | 22 (18) |
| Current | 4 (7) | 2 (3) | 6 (5) |
| ECOG PS | |||
| 0 | 5 (9) | 4 (7) | 9 (7) |
| 1 | 36 (61) | 43 (69) | 79 (65) |
| 2 | 18 (30) | 15 (24) | 33 (28) |
| EGFR mutation | |||
| Exon 19 deletion | 39 (66) | 35 (57) | 74 (61) |
| Exon 21 L858R | 20 (34) | 27 (43) | 47 (39) |
| EGFR TKI | |||
| Gefitinib | 54 (91) | 49 (79) | 103 (85) |
| Erlotinib | 5 (9) | 13 (21) | 18 (15) |
| Extracranial metastasis | |||
| None | 19 (32) | 4 (7) | 23 (19) |
| One | 18 (31) | 28 (45) | 46 (38) |
| ≥Two | 22 (37) | 30 (48) | 52 (43) |
| Site of extracranial metastasis | |||
| Bone | 28 (48) | 40 (65) | 68 (56) |
| Lung | 17 (29) | 22 (36) | 39 (32) |
| Liver | 10 (17) | 10 (16) | 20 (17) |
| Pleura | 6 (10) | 17 (27) | 23 (19) |
| Adrenal gland | 9 (15) | 2 (3) | 11 (9) |
| Other | 4 (7) | 5 (8) | 9 (7) |
| Number of BMs | |||
| <5 | 21 (36) | 15 (24) | 36 (30) |
| ≥5 | 38 (64) | 47 (76) | 85 (70) |
| Co-existing LMS | |||
| Yes | 10 (17) | 10 (16) | 20 (17) |
| No | 49 (83) | 52 (84) | 101 (93) |
| BM-related symptoms | |||
| Yes | 28 (48) | 12 (20) | 40 (33) |
| No | 31 (52) | 50 (80) | 81 (67) |
ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, BM brain metastasis, LMS leptomeningeal carcinomatosis